Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $22.6 million.

  • Ani Pharmaceuticals' Depreciation & Amortization (CF) rose 4371.35% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year increase of 5151.93%. This contributed to the annual value of $67.7 million for FY2024, which is 1327.96% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Depreciation & Amortization (CF) is $22.6 million, which was up 4371.35% from $23.3 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization (CF) peaked at $23.3 million during Q2 2025, and registered a low of $10.9 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $14.7 million (2024), whereas its average is $15.9 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Depreciation & Amortization (CF) crashed by 254.85% in 2021 and then surged by 5840.65% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Depreciation & Amortization (CF) stood at $13.7 million in 2021, then grew by 13.8% to $15.6 million in 2022, then fell by 2.43% to $15.2 million in 2023, then skyrocketed by 48.74% to $22.6 million in 2024, then increased by 0.14% to $22.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $22.6 million in Q3 2025, compared to $23.3 million in Q2 2025 and $22.9 million in Q1 2025.